Prognostic Impact of Synchronous and Metachronous Second Primary Cancers in Laryngeal Cancer Patients Treated With Radiotherapy: Variable With Time-Varying Effects and Cox Proportional Hazard Analyses.

IF 1.4 4区 医学 Q4 ONCOLOGY
Akikazu Kobori, Chiyoko Makita, Osamu Tanaka, Sunaho Okada, Yuichi Kajiura, Nansei Yamada, Masayuki Matsuo
{"title":"Prognostic Impact of Synchronous and Metachronous Second Primary Cancers in Laryngeal Cancer Patients Treated With Radiotherapy: Variable With Time-Varying Effects and Cox Proportional Hazard Analyses.","authors":"Akikazu Kobori, Chiyoko Makita, Osamu Tanaka, Sunaho Okada, Yuichi Kajiura, Nansei Yamada, Masayuki Matsuo","doi":"10.1111/ajco.14206","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Patients with laryngeal and other head and neck cancers face a high risk of developing second primary cancers. This retrospective cohort study evaluated the prognostic value of second primary cancers in laryngeal cancer patients treated with radiotherapy.</p><p><strong>Methods: </strong>We retrospectively investigated patients with laryngeal cancer who underwent radiotherapy, and evaluated the incidence and relative risk of synchronous and metachronous second primary cancers in a single-institution cohort.</p><p><strong>Results: </strong>Between January 2007 and December 2021, 138 patients with laryngeal cancer were analyzed. The median follow-up period was 5.2 years. The 5-year overall survival rate was 82.4% and the progression-free survival rate was 71.9%. Synchronous and metachronous second primary cancers were observed in 15 (10.9%) and 38 (27.5%) patients, respectively, during the follow-up period. The cumulative incidence of metachronous second primary cancers was 23.3% at 5 years. Moreover, deaths from laryngeal cancer, other cancers, and noncancer illnesses accounted for 3.6% (5 patients), 12.3% (17 patients), and 10.9% (17 patients), respectively, with most deaths from causes other than laryngeal cancer occurring after the first 5 years. Synchronous second primary cancer was a significant prognostic factor of poor outcomes (hazard ratio, 4.42; 95% confidence interval, 1.93-10.13) on time-independent multivariate analysis, and metachronous second primary cancer was a significant prognostic factor of poor outcomes (hazard ratio, 4.55; 95% confidence interval, 2.09-9.91) in the time-dependent Cox proportional hazards model.</p><p><strong>Conclusion: </strong>Synchronous and metachronous second primary cancers are significant prognostic factors for patients with laryngeal cancer treated with radiotherapy.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":"e14206"},"PeriodicalIF":1.4000,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia-Pacific journal of clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ajco.14206","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: Patients with laryngeal and other head and neck cancers face a high risk of developing second primary cancers. This retrospective cohort study evaluated the prognostic value of second primary cancers in laryngeal cancer patients treated with radiotherapy.

Methods: We retrospectively investigated patients with laryngeal cancer who underwent radiotherapy, and evaluated the incidence and relative risk of synchronous and metachronous second primary cancers in a single-institution cohort.

Results: Between January 2007 and December 2021, 138 patients with laryngeal cancer were analyzed. The median follow-up period was 5.2 years. The 5-year overall survival rate was 82.4% and the progression-free survival rate was 71.9%. Synchronous and metachronous second primary cancers were observed in 15 (10.9%) and 38 (27.5%) patients, respectively, during the follow-up period. The cumulative incidence of metachronous second primary cancers was 23.3% at 5 years. Moreover, deaths from laryngeal cancer, other cancers, and noncancer illnesses accounted for 3.6% (5 patients), 12.3% (17 patients), and 10.9% (17 patients), respectively, with most deaths from causes other than laryngeal cancer occurring after the first 5 years. Synchronous second primary cancer was a significant prognostic factor of poor outcomes (hazard ratio, 4.42; 95% confidence interval, 1.93-10.13) on time-independent multivariate analysis, and metachronous second primary cancer was a significant prognostic factor of poor outcomes (hazard ratio, 4.55; 95% confidence interval, 2.09-9.91) in the time-dependent Cox proportional hazards model.

Conclusion: Synchronous and metachronous second primary cancers are significant prognostic factors for patients with laryngeal cancer treated with radiotherapy.

同步和异时性喉癌患者放疗对预后的影响:时变效应和Cox比例风险分析。
目的:喉癌和其他头颈癌患者面临发展为第二原发癌的高风险。本回顾性队列研究评估第二原发癌在喉癌放疗患者中的预后价值。方法:我们回顾性调查了接受放疗的喉癌患者,并在单机构队列中评估同步和异时性第二原发癌的发病率和相对风险。结果:2007年1月至2021年12月,对138例喉癌患者进行了分析。中位随访期为5.2年。5年总生存率为82.4%,无进展生存率为71.9%。在随访期间,分别有15例(10.9%)和38例(27.5%)患者出现同步和异时性第二原发癌。5年时,异时性第二原发癌的累积发病率为23.3%。此外,喉癌、其他癌症和非癌症疾病的死亡分别占3.6%(5例)、12.3%(17例)和10.9%(17例),其中大多数死于喉癌以外的原因发生在头5年后。同步第二原发癌是不良预后的重要预后因素(风险比,4.42;95%可信区间,1.93-10.13),异时性第二原发癌是不良预后的重要预后因素(风险比,4.55;95%置信区间为2.09-9.91)。结论:同步和异时性第二原发癌是喉癌放疗患者预后的重要因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.40
自引率
0.00%
发文量
175
审稿时长
6-12 weeks
期刊介绍: Asia–Pacific Journal of Clinical Oncology is a multidisciplinary journal of oncology that aims to be a forum for facilitating collaboration and exchanging information on what is happening in different countries of the Asia–Pacific region in relation to cancer treatment and care. The Journal is ideally positioned to receive publications that deal with diversity in cancer behavior, management and outcome related to ethnic, cultural, economic and other differences between populations. In addition to original articles, the Journal publishes reviews, editorials, letters to the Editor and short communications. Case reports are generally not considered for publication, only exceptional papers in which Editors find extraordinary oncological value may be considered for review. The Journal encourages clinical studies, particularly prospectively designed clinical trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信